Melan-A, A New Melanocytic Differentiation Marker

Busam, Klaus J.; Jungbluth, Achim A.

doi:10.1097/00125480-199901000-00002

Cited by 144 publications

(87 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5,20 In 1 study, only 68% of human adrenocortical adenomas and 100% of adrenocortical carcinomas were positive for Melan A. 18 As in humans, 5,6,11 the canine granulosa cell tumors in this study gave the weakest and most inconsistent reaction for Melan A.…”

Section: Discussionmentioning

confidence: 44%

“…Nuclear staining with Melan A antibodies has not been reported in human steroid-producing tumors or in human or canine melanomas. 5,6,11,17,18,20 This pattern of staining might indicate that the molecule recognized by Melan A antibody is different from that reported in human tumors. Alternatively, the expression of this cross-reacting antigen might differ among canine tumors.…”

Section: Discussionmentioning

confidence: 84%

“…11 Overall, the staining pattern in adrenal, testicular, and ovarian neoplasms was similar to that described in human tumors. 5,6,11 However, the number of positive cases for a given type of tumor and the location of the staining was somewhat different. Only 65% of canine adrenocortical carcinomas were positive for Melan A.…”

Section: Discussionmentioning

confidence: 99%

“…8,12 This protein is coded by the MART 1 gene 9,12 and is a highly specific immunohistochemical marker for human melanomas. 4,6,8 More than 90% of canine oral melanomas are also positive for Melan A. 17 In recent studies, a monoclonal antibody (clone A103) to Melan A was used to detect human steroid-producing cells (and their corresponding tumors), including adrenal cortical cells, granulosa cells of the ovary, and Leydig cells of the testicle.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Immunoreactivity of A103, An Antibody to Melan A, in Canine Steroid-Producing Tissues and their Tumors

et al. 2001

View full text Add to dashboard Cite

Abstract. The monoclonal antibody A103 to the melanocytic differentiation antigen Melan A stains human steroid-producing cells and their tumors. A total of 200 formalin-fixed, paraffin-embedded canine normal tissues and hyperplastic and neoplastic lesions of the adrenal gland, testis, and ovary were immunohistochemically tested for Melan A with antibody A103. Leydig cell tumors (23/23, 100%), Sertoli cell tumors (14/15, 93%), and adrenocortical adenomas (12/13, 92%) were consistently positive. Adrenocortical carcinomas (23/35, 65%) and granulosa cell tumors (10/17, 59%) were less frequently positive. All pheochromocytomas, seminomas, and dysgerminomas were negative. The pattern of staining was cytoplasmic, but nuclear staining was also frequently seen in normal Leydig cells and their tumors. As in human tumors, immunohistochemistry for Melan A stains many canine steroid-producing tumors and can be used to distinguish these tumors from those of nonstereidogenic cells.Melan A belongs to a group of melanocytic differentiation antigens, including tyrosinase, gp 100, human melanosome-associated antigen, and microphthalmia transcription factor. 1,3,10,13,19 Melan A is an antigen that is recognized by autologous cytotoxic T cells. 8,12 This protein is coded by the MART 1 gene 9,12 and is a highly specific immunohistochemical marker for human melanomas. 4,6,8 More than 90% of canine oral melanomas are also positive for Melan A. 17 In recent studies, a monoclonal antibody (clone A103) to Melan A was used to detect human steroid-producing cells (and their corresponding tumors), including adrenal cortical cells, granulosa cells of the ovary, and Leydig cells of the testicle. 5,11,18,20 The apparent absence of Melan A in these tissues suggests that reactivity is the result of cross-reaction with a similar protein. 4 The diagnosis of canine endocrine tumors can be challenging, especially when it is necessary to distinguish between cortical and medullary adrenal tumors and their metastases. In the present report, the immunohistochemical detection of Melan A in formalinfixed, paraffin-embedded tissues of normal and neoplastic tissues from the adrenal gland, ovary, and testis of dogs is described. Health Diagnostic Laboratory databases were searched for biopsies and necropsies containing adrenal gland, ovarian, or testicular tumors. A total of 200 normal, hyperplastic, or neoplastic tissues, including testicular tumors (Leydig cell tumor, Sertoli cell tumor, and seminoma), ovarian tumors (granulosa-theca, luteoma, dysgerminoma, and carcinoma), and adrenal lesions (adrenal cortical hyperplasia, adrenocortical adenoma, adrenocortical carcinoma, and pheochromocytoma) corresponding to 182 canine accessions were selected for this study. Diagnoses were initially made by the case coordinator; every case was reviewed by another pathologist (JAR) using reported classification criteria. 2,14,15 If discrepancies in the diagnosis based on hematoxylin and eosin-stained sections were found, a consensus among 3 pathologists was reached. Tissu...

show abstract

Section: Discussionmentioning

confidence: 44%

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Immunoreactivity of A103, An Antibody to Melan A, in Canine Steroid-Producing Tissues and their Tumors

et al. 2001

View full text Add to dashboard Cite

show abstract

“…This rate of immunopositivity confirmed the high level of expression previously reported by others in primary and metastatic melanoma. 13,14,16,18,20 Loss of Melan-A/MART-1 immunostaining significantly correlated with increased Breslow thickness. These results are in agreement with a study 21 that found an increased rate of Melan-A/MART-1 negative tumors in advanced compared with early stage primary melanomas (approximately 25% and 15%, respectively).…”

Section: Table II -Correlation Between Melan-a/mart-1 Staining Pattermentioning

confidence: 96%

Expression of melan-a/MART-1 antigen as a prognostic factor in primary cutaneous melanoma

et al. 2001

View full text Add to dashboard Cite

The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis

Hoesl¹,

Fröhlich²,

Posch

et al. 2021

Molecular Oncology

View full text Add to dashboard Cite

show abstract

Melan-A, A New Melanocytic Differentiation Marker

Cited by 144 publications

References 0 publications

Immunoreactivity of A103, An Antibody to Melan A, in Canine Steroid-Producing Tissues and their Tumors

Immunoreactivity of A103, An Antibody to Melan A, in Canine Steroid-Producing Tissues and their Tumors

Expression of melan-a/MART-1 antigen as a prognostic factor in primary cutaneous melanoma

The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis

Contact Info

Product

Resources

About